NCT00264576已完成2 期
A Phase 2, Observer-Blinded, Randomized, Multicenter Study in Healthy Adults to Evaluate Safety and Tolerability and to Compare Immunogenicity of a Single Dose of Either an Investigational Trivalent Inactivated Influenza Vaccine Produced in Mammalian Cell Culture or a US-licensed Trivalent Inactivated Influenza Vaccine (Fluvirin®) Produced in Embryonated Hen Eggs
Novartis Vaccines4 个研究点 分布在 1 个国家目标入组 613 人开始时间: 2005年10月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 613
- 试验地点
- 4
- 主要终点
- Geometric Mean Titers (GMT) After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANOVA Method.
研究概览
简要总结
The purpose of this study is to evaluate the safety and immunogenicity of cell culture-derived, inactivated, subunit influenza vaccine in comparison to licensed Fluvirin vaccine administered to healthy adults ages 18 < 50 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 49 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •18 to <50 years of age;
- •able to comprehend and follow all required study procedures;
- •able and willing to provide written informed consent prior to study entry;
- •available for all the visits scheduled in the study;
- •in general good health as determined by:
- •subject-reported medical history,
- •physical examination by a qualified study nurse, a physician's assistant, or a physician,
- •clinical judgment of the investigator; among all female volunteers, evidence of a negative pregnancy test conducted on the same day as and prior to study vaccination, and agreement to practice adequate contraception for at least 6 weeks after vaccination as further described in the protocol.
排除标准
- •received influenza vaccine within the past 6 months;
- •laboratory-confirmed influenza disease in the past 6 months;
- •any acute respiratory disease or infection requiring systemic antibiotic or antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis was acceptable) or fever ≥38°C (100.4°F) within the past 3 days;
- •receipt of another investigational agent within 90 days or before completion of the safety follow-up period in another study, whichever was longer, prior to enrollment, and unwilling to refuse participation in another investigational study through the end of the study;
- •any history of or current serious disease, such as: d) cancer (except for benign or localized skin cancer), e) autoimmune disease (including rheumatoid arthritis), f) advanced arteriosclerotic disease or diabetes mellitus, g) chronic obstructive pulmonary disease (COPD), h) acute, chronic, or progressive hepatic disease, i) acute, chronic, or progressive renal disease, j) congestive heart failure, k) bleeding diathesis, l) an inherited genetic anomaly (known cytogenic disorders, e.g., Down's Syndrome), m) any other serious, acute, or chronic disease including progressive neurological disease or seizure disorder unrelated to fever;
- •surgery or hospitalization planned during the study period;
- •history of any anaphylaxis, serious vaccine reactions, vaccine-associated oculorespiratory syndrome, or allergy to eggs, egg products, mercury-containing compounds (such as sodium-ethyl-mercuro-thio-salicylate), or any other vaccine component or component of the potential packaging materials (latex);
- •known or suspected disease of the immune system, or receiving immunosuppressive therapy, including use of: n) systemic corticosteroids, known to be associated with suppression of the hypothalamic-pituitary-adrenal (HPA) axis (i.e., systemic corticosteroids [15 mg/day of prednisone or its equivalent] or chronic use of inhaled high potency corticosteroids [budesonide 800 μg/day or fluticasone 750 μg/day]), both within the previous 60 days, o) receipt of immunostimulants within 60 days, p) receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within the 3 months prior to study entry or anticipated during the full length of the study;
- •at high risk for developing an immunocompromising disease;
- •history of (or current) drug or alcohol abuse that in the investigator's opinion would interfere with safety of the subject or the evaluation of study objectives;
- •pregnant or breastfeeding;
- •if female of childbearing potential, refusal to use a reliable contraceptive method, as described further in the protocol, during the first 6 weeks after vaccination;
- •if female of childbearing potential and sexually active, has not used any of the following birth control methods for the specified time period prior to study entry:
- •hormonal (e.g., oral, injection, transdermal patch, implant, cervical ring), barrier (e.g., condom with spermicide or diaphragm with spermicide), or intrauterine device (e.g., IUD) for 2 months or more prior to study entry,
- •monogamous relationship with vasectomized partner: partner has been vasectomized for 6 months or more prior to the subject's study entry;
- •obese (e.g., with a body mass index [BMI] ≥35, where BMI reflects obesity and not high muscle mass);
- •any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives or might interfere with the safety of the study subject.
研究组 & 干预措施
TIV
Active Comparator
Received one dose of egg-derived trivalent vaccine (TIV).
干预措施: Influenza Virus Vaccine (Biological)
cTIV
Experimental
Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
干预措施: Influenza Virus Vaccine (Biological)
结局指标
主要结局
Geometric Mean Titers (GMT) After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANOVA Method.
时间窗: 3 weeks postvaccination (Day 22)
Non-inferiority was measured by the ratio of postvaccination geometric mean titers (cTIV vs. eTIV_f) against all three vaccine strains as assessed by egg-derived antigen and cell-derived antigen haemagglutination inhibition (HI) assay.
Geometric Mean Titers (GMT) After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANCOVA Method.
时间窗: 3 weeks postvaccination (Day 22)
Non-inferiority was measured by the ratio of postvaccination geometric mean titers (cTIV vs. eTIV_f) against all three vaccine strains as assessed by egg-derived antigen and cell-derived antigen haemagglutination inhibition (HI) assay.
次要结局
- Geometric Mean Ratio After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANOVA Method.(3 weeks postvaccination (Day 22))
- Geometric Mean Ratio After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANCOVA Method.(3 weeks postvaccination (Day 22))
- Geometric Mean Titers (GMT) Before and After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANOVA Method(3 weeks postvaccination (Day 22))
- Percentages of Subjects With Haemagglutination Inhibition (HI) Antibody Titer ≥ 40.(3 weeks postvaccination (Day 22))
- Percentages of Subjects With Seroconversion.(3 weeks postvaccination (Day 22))
- Number of Subjects Reporting Local and Systemic Reactions(7 days postvaccination)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly SubjectsInfluenza, HumanNCT02344134SK Chemicals Co., Ltd.1,155
已完成
3 期
Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney TransplantsKidney Transplant RejectionNCT03363945Medeor Therapeutics, Inc.30
撤回
2 期
Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney TransplantsKidney Transplant RejectionNCT03606746Medeor Therapeutics, Inc.
已完成
2 期
Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, BangladeshDengueNCT02678455National Institute of Allergy and Infectious Diseases (NIAID)192
已完成
3 期
Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and AboveHuman InfluenzaNCT01880697Novartis Vaccines126